JP2020530496A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530496A5
JP2020530496A5 JP2020530436A JP2020530436A JP2020530496A5 JP 2020530496 A5 JP2020530496 A5 JP 2020530496A5 JP 2020530436 A JP2020530436 A JP 2020530436A JP 2020530436 A JP2020530436 A JP 2020530436A JP 2020530496 A5 JP2020530496 A5 JP 2020530496A5
Authority
JP
Japan
Prior art keywords
methyl
chlorophenyl
amino
pharmaceutically acceptable
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2020530436A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530496A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/046057 external-priority patent/WO2019032859A1/en
Publication of JP2020530496A publication Critical patent/JP2020530496A/ja
Publication of JP2020530496A5 publication Critical patent/JP2020530496A5/ja
Ceased legal-status Critical Current

Links

JP2020530436A 2017-08-09 2018-08-09 タンパク質アルギニンメチルトランスフェラーゼ5(prmt5)の選択的阻害剤 Ceased JP2020530496A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762543141P 2017-08-09 2017-08-09
US62/543,141 2017-08-09
US201862630581P 2018-02-14 2018-02-14
US62/630,581 2018-02-14
US201862664442P 2018-04-30 2018-04-30
US62/664,442 2018-04-30
PCT/US2018/046057 WO2019032859A1 (en) 2017-08-09 2018-08-09 SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)

Publications (2)

Publication Number Publication Date
JP2020530496A JP2020530496A (ja) 2020-10-22
JP2020530496A5 true JP2020530496A5 (https=) 2021-09-16

Family

ID=63405398

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020530436A Ceased JP2020530496A (ja) 2017-08-09 2018-08-09 タンパク質アルギニンメチルトランスフェラーゼ5(prmt5)の選択的阻害剤

Country Status (18)

Country Link
US (4) US10570140B2 (https=)
EP (2) EP3939986A1 (https=)
JP (1) JP2020530496A (https=)
KR (1) KR20200036922A (https=)
CN (1) CN111527099B (https=)
AU (1) AU2018313910B2 (https=)
BR (1) BR112020002736A2 (https=)
CA (1) CA3072439A1 (https=)
DK (1) DK3665179T3 (https=)
ES (1) ES2885180T3 (https=)
IL (1) IL272519B (https=)
MA (1) MA49840A (https=)
MX (1) MX2020001598A (https=)
PL (1) PL3665179T3 (https=)
PT (1) PT3665179T (https=)
UA (1) UA126481C2 (https=)
WO (1) WO2019032859A1 (https=)
ZA (1) ZA202000773B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3939986A1 (en) * 2017-08-09 2022-01-19 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
AU2019235912B2 (en) * 2018-03-14 2024-03-21 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
US12552826B2 (en) 2018-08-07 2026-02-17 Merck Sharp & Dohme Llc PRMT5 inhibitors
US12173026B2 (en) * 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3924360A1 (en) * 2019-02-13 2021-12-22 Prelude Therapeutics, Incorporated Selective inhibitor of protein arginine methyltransferase 5 (prmt5)
IL318073A (en) * 2019-03-25 2025-02-01 California Inst Of Techn PRMT5 inhibitors and their uses
JP2022526604A (ja) * 2019-04-05 2022-05-25 プレリュード・セラピューティクス・インコーポレイテッド タンパク質アルギニンメチルトランスフェラーゼ5の選択的阻害剤
WO2020206289A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
CN114126614A (zh) * 2019-05-30 2022-03-01 安杰斯制药公司 作为prmt5抑制剂的杂环化合物
WO2021055797A1 (en) * 2019-09-18 2021-03-25 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EP4048674A2 (en) * 2019-10-21 2022-08-31 Accent Therapeutics, Inc. Mettl3 modulators
KR20220086628A (ko) * 2019-10-22 2022-06-23 루핀 리미티드 Prmt5 저해제의 약학적 조합물
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
WO2022026892A1 (en) 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers
US11685744B2 (en) 2020-09-21 2023-06-27 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
US20220251088A1 (en) * 2020-12-10 2022-08-11 Prelude Therapeutics, Incorporated Processes for Making PRMT5 Inhibitors
UY39565A (es) * 2020-12-16 2022-06-30 Amgen Inc Inhibidores de prmt5 novedosos
CA3205652A1 (en) 2020-12-18 2022-06-23 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
CN117157297A (zh) * 2021-07-20 2023-12-01 上海齐鲁制药研究中心有限公司 Prmt5抑制剂
US20230181589A1 (en) * 2021-12-03 2023-06-15 The Trustees Of Indiana University Prmt5 inhibitors for ocular therapy
US11939340B2 (en) 2022-01-21 2024-03-26 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
WO2023150612A1 (en) 2022-02-03 2023-08-10 Prelude Therapeutics, Incorporated Cdk inhibitors and their use as pharmaceuticals
US20240018136A1 (en) 2022-03-09 2024-01-18 Prelude Therapeutics, Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
CA3245813A1 (en) 2022-03-23 2023-09-28 Prelude Therapeutics, Incorporated POLYMORPHIC COMPOUNDS AND THEIR USES
CN116655638B (zh) * 2022-05-12 2024-01-26 上海齐鲁制药研究中心有限公司 氘代prmt5抑制剂
US20240150340A1 (en) 2022-10-06 2024-05-09 Prelude Therapeutics Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
WO2024216249A1 (en) 2023-04-14 2024-10-17 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
CN116554194A (zh) * 2023-05-23 2023-08-08 江苏八巨药业有限公司 一种卡培他滨中间体的合成方法
WO2025064402A1 (en) * 2023-09-22 2025-03-27 St. Jude Children's Research Hospital, Inc. Method for treating sickle cell disease by targeting senescent cells

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
DE102010060118A1 (de) * 2010-10-22 2012-04-26 Röhm Gmbh Stirnseitenmitnehmer
US9145438B2 (en) 2010-12-03 2015-09-29 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
ES2637113T3 (es) * 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
DK2935222T3 (en) * 2012-12-21 2019-01-07 Epizyme Inc PRMT5 INHIBITORS AND APPLICATIONS THEREOF
WO2014153214A1 (en) * 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
CA2942833A1 (en) * 2013-03-15 2014-09-18 Ohio State Innovation Foundation Inhibitors of prmt5 and methods of their use
US20170198006A1 (en) * 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US20170210751A1 (en) * 2014-06-25 2017-07-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016066582A1 (en) 2014-10-28 2016-05-06 Bci Pharma Nucleoside kinase inhibitors
KR101719881B1 (ko) * 2014-12-22 2017-03-24 삼성전기주식회사 렌즈 모듈
MX2017010844A (es) * 2015-02-24 2017-12-07 Pfizer Derivados de nucleosidos sustituidos utiles como agentes anticancerosos.
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI870767B (zh) * 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
AU2017230658B2 (en) 2016-03-10 2021-03-04 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
WO2017218802A1 (en) 2016-06-15 2017-12-21 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018065365A1 (en) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
WO2018075601A1 (en) 2016-10-18 2018-04-26 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018085833A2 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
WO2018085818A1 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US11220524B2 (en) 2017-02-20 2022-01-11 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
WO2018152501A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018160855A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EP3939986A1 (en) 2017-08-09 2022-01-19 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2019084470A1 (en) 2017-10-26 2019-05-02 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
US12552826B2 (en) 2018-08-07 2026-02-17 Merck Sharp & Dohme Llc PRMT5 inhibitors

Similar Documents

Publication Publication Date Title
JP2020530496A5 (https=)
CN114599361B (zh) Prmt5抑制剂的药物组合物
ES2612378T3 (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas como inhibidores de cinasa MKNK
CN102015739B (zh) 化合物以及用于治疗的方法
US20230053946A1 (en) Combinations
IL282916B1 (en) Fused cyclic chemical compounds and their uses in the treatment of ras-mediated diorders
JP7577672B2 (ja) Flt3阻害剤及び低メチル化剤を含む急性骨髄性白血病の治療のための薬学的組成物
ES2639402T3 (es) 2,3-dihidroimidazo[1,2-c]quinolinas sustituidas con arilaminoalcohol
RU2006128426A (ru) Производные тиофенав в качестве ингибиторов снк 1
EA012869B1 (ru) Замещённые пиримидины, композиции на их основе и применение замещенных пиримидинов в качестве ингибиторов протеинкиназ
SA111320735B1 (ar) إيميدازوبيريدازينات مستبدلة
JP2016516821A5 (https=)
JP2015515961A5 (https=)
JP2015505816A5 (https=)
US20230087941A1 (en) Combinations
US20230068370A1 (en) Combinations
TW202015693A (zh) 治療pi3k 相關病症之給藥方案
KR20220119442A (ko) 조합
ES2863250T3 (es) Tratamiento de trastornos neurológicos
US20230042653A1 (en) Combinations
WO2021127042A1 (en) Combinations
KR20220119427A (ko) 조합
US20230054767A1 (en) Combinations
US20220241310A1 (en) Thiarabine- and thiarabine prodrug-based treatments